Evaluation of Tolerability and Safety of “Allergovac Poliplus” in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice

Conditions:   Allergic Rhinitis;   Rhinoconjunctivitis;   Asthma
Intervention:   Biological: Allergovac Poliplus
Sponsor:   BIAL Industrial Farmacéutica S.A.
Not yet recruiting – verified July 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Health, environmental tracker could head off asthma attacks without drugs – FierceMedicalDevices (press release) (registration)


NDTV

Health, environmental tracker could head off asthma attacks without drugs
FierceMedicalDevices (press release) (registration)
Currently, asthma treatment involves avoiding irritants and taking medication to relieve symptoms. Researchers at North Carolina State University have created a wearable system that more concretely monitors potential environmental irritants and could …
New Wearable Device Could Predict, Prevent Asthma AttacksNDTV
Wearable system, new devices aim to predict, prevent asthma attacksWRAL Tech Wire
NC State Scientists Develop Wearable System To Predict, Prevent Asthma AttacksLung Disease News

all 6 news articles »

View full post on asthma – Google News

People without asthma can experience breathing difficulties during bushfires … – ABC Online


ABC Online

People without asthma can experience breathing difficulties during bushfires
ABC Online
Irritants in the air can trigger people without asthma to experience symptoms of altered breathing during bushfire season. Chair of the National Asthma Council's pharmacist group Marcus Weidinger said it was not just people with diagnosed respiratory …

and more »

View full post on asthma – Google News

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Condition:   Rhinitis, Allergic, Seasonal
Interventions:   Biological: MK-3641;   Biological: Placebo;   Drug: Self-injectable epinephrine;   Drug: Albuterol/Salbutamol;   Drug: Loratadine;   Drug: Olopatadine;   Drug: Mometasone furoate monohydrate
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting – verified June 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.

Condition:   Bronchial Asthma
Interventions:   Drug: Intravenous magnesium sulfate;   Drug: Inhaled budesonide;   Drug: normal saline
Sponsor:   Hamad Medical Corporation
Recruiting – verified May 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days